XTL Biopharmaceuticals Ltd. has received a notification letter from Nasdaq stating that it does not meet the continued listing requirement due to its closing bid price below $1 per share. The company has 180 days to regain compliance by achieving a minimum bid price of $1 for ten consecutive business days. If XTL fails to comply, it may be eligible for additional time by meeting other listing requirements. XTL is actively evaluating options to regain compliance with Nasdaq’s rules. The company holds a web data AI company and an IP portfolio focused on treating Lupus disease.

Read more at GlobeNewswire: XTL Announces Receipt of Nasdaq Notification Letter